Recursion (NASDAQ: RXRX) director sale under 10b5-1 trading plan
Rhea-AI Filing Summary
Recursion Pharmaceuticals director Christopher Gibson reported a planned share sale and related conversion. On January 20, 2026, he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock at $0 per share pursuant to the Class B conversion feature. The same day, he sold 40,000 Class A shares at $4.47 per share under a Rule 10b5-1 trading plan adopted on May 12, 2025.
After these transactions, Gibson directly owned 913,839 shares of Class A Common Stock. He also reported additional indirect Class A holdings through entities he manages or serves as trustee, including 386,000 shares via LAHWRAN-3 LLC, 388,000 shares via LAHWRAN-4 LLC, and 50,000 shares via the Gibson Family Trust, as well as multiple outstanding stock options with various exercise prices and expirations.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 40,000 | $0.00 | -- |
| Conversion | Class A Common Stock | 40,000 | $0.00 | -- |
| Sale | Class A Common Stock | 40,000 | $4.47 | $179K |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (1)
- Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
FAQ
What insider transactions did RXRX director Christopher Gibson report?
Christopher Gibson reported that on January 20, 2026 he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock at $0, and then sold 40,000 Class A shares at $4.47 per share.
Was the January 20, 2026 RXRX insider sale under a 10b5-1 plan?
Yes. The filing states that the transaction was conducted under a Rule 10b5-1 trading plan adopted by Christopher Gibson on May 12, 2025.
What is the relationship between RXRX Class B and Class A Common Stock in this filing?
The footnotes state that each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
What stock options in RXRX does Christopher Gibson report holding?
The Form 4 lists several stock options (rights to buy Class A Common Stock) with exercise prices ranging from $2.48 to $11.40 per share and expiration dates from December 30, 2030 to February 3, 2035, subject to monthly vesting schedules described in the footnotes.
What is Christopher Gibson’s role at Recursion Pharmaceuticals (RXRX)?
In this filing, Christopher Gibson is identified as a director of Recursion Pharmaceuticals, Inc.
